drugset
drugset / Trial / NCT03877289

Efficacy of Oxybutynin in Paediatric Cystitis

NCT03877289 ↗

Phase 4 Completed 81 enrolled University of Calgary
RandomizedParallel-groupTriple-blindSupportive care

Summary

The primary goal of this study is to determine if the addition of the bladder antispasmotic oxybutynin to standard antimicrobial therapy in the treatment of childhood cystitis will decrease the associated pain and discomfort. A randomized, double blind, placebo-controlled clinical trial design will be used. The second goal of this study will be to describe the nature and duration of symptoms associated with uncomplicated cystitis in the paediatric age group. Finally, adverse side effects associated with short term use of oxybutynin will be monitored.

Timeline

Start
2008-10
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxybutynin Small molecule 2.5 mg Oral
Subject Oxybutynin Small molecule 5 mg Oral
Background CEPHACETRILE Small molecule — Oral
Background CEPHALEXIN ANHYDROUS Small molecule — Oral
Background CEPHALORIDINE Small molecule — Oral
Background CEPHALOTHIN Small molecule — Oral
Background CEPHAPIRIN Small molecule — Oral
Background CEPHRADINE Small molecule — Oral
Background Cefatrizine Small molecule — Oral
Background Cefazolin Small molecule — Oral
Background Cefdroxil Unknown — Oral
Background Cefixime Other / unclassified — Oral
Background Cefroxadine Small molecule — Oral
Background Cefuroxime Small molecule — Oral
Background Nitrofurantoin Unknown — Oral
Background Sulfamethoxazole Small molecule — Oral
Background Trimethoprim Small molecule — Oral
Background amoxicillin/clavulanic acid Unknown — Oral

Indications

cystitis